Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Retained Earnings (2024 - 2025)

Pelthos Therapeutics has reported Retained Earnings over the past 2 years, most recently at -$64.8 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$64.8 million for Q4 2025, down 201.72% from a year ago — trailing twelve months through Dec 2025 was -$64.8 million (down 201.72% YoY), and the annual figure for FY2025 was -$64.8 million, down 201.72%.
  • Retained Earnings for Q4 2025 was -$64.8 million at Pelthos Therapeutics, down from -$43.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for PTHS hit a ceiling of -$16.1 million in Q1 2024 and a floor of -$64.8 million in Q4 2025.